# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000886163-17-000049
Filing Date
2017-04-14
Accepted
2017-04-14 09:24:22
Documents
11
Period of Report
2017-04-14
Effectiveness Date
2017-04-14

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | lgnd-2017annualmeetingproxy.htm | DEF 14A | 905552
2 |  | image0.jpg | GRAPHIC | 9775
3 |  | image1a01.gif | GRAPHIC | 565
4 |  | image2.gif | GRAPHIC | 1174
5 |  | image3.gif | GRAPHIC | 612
6 |  | image4.gif | GRAPHIC | 431
7 |  | ligandpharmaceuticalsnot002.jpg | GRAPHIC | 172051
8 |  | performancegrapha02.jpg | GRAPHIC | 267676
9 |  | proxycard1032417v2001.jpg | GRAPHIC | 201184
10 |  | proxycard032817001.jpg | GRAPHIC | 235727
11 |  | proxycard2032417002.jpg | GRAPHIC | 105130
| Complete submission text file | 0000886163-17-000049.txt |  | 2263779

Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33093 | Film No.: 17762236
SIC: 2834 Pharmaceutical Preparations